Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019
Seven new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its September 2019 meeting.
The Committee recommended granting a marketing authorisation for Xospata* (gilteritinib) for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. AML is a rare type of cancer of the white blood cells (cells that fight infections). It affects approximately 1 in 10,000 people in the European Union. Xospata was reviewed under EMA's accelerated assessment procedure, reserved for medicines of major public health interest.
Qtrilmet (metformin hydrochloride / saxagliptin / dapagliflozin) received a positive opinion from the CHMP for the treatment of type 2 diabetes mellitus.
Senstend (lidocaine / prilocaine), which was evaluated in an informed consent application, received a positive opinion for the treatment of premature ejaculation in adult men. An informed consent application makes use of data from the dossier of a previously authorised medicine, with the marketing authorisation holder of that medicine giving consent for the use of their data in the application.
The CHMP recommended granting marketing authorisations for three generic medicines: Arsenic trioxide Accord (arsenic trioxide), for the treatment of acute promyelocytic leukaemia; Bortezomib Fresenius Kabi (bortezomib), for the treatment of multiple myeloma and mantle cell lymphoma; and Ivozall (clofarabine), for the treatment of acute lymphoblastic leukaemia in paediatric patients.
Eight recommendations on extensions of therapeutic indication
The Committee recommended extensions of indication for Bavencio, Benlysta, Docetaxel Zentiva, Dupixent, Lucentis, Remisima, Taxotere and Trulicity.
Agenda and minutes
The agenda of the September 2019 meeting is published on EMA's website. Minutes of the July 2019 CHMP meeting will be published in the coming weeks.
Key figures from the September 2019 CHMP meeting are represented in the graphic below.
*This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products (COMP) at the time of approval to determine whether the information available to date allows maintaining the medicine's orphan status and granting the medicine ten years of market exclusivity.
|Name of medicine||Xospata|
|Marketing-authorisation applicant||Astellas Pharma Europe B.V.|
|Therapeutic indication||Treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation|
|Name of medicine||Bavencio|
|Marketing-authorisation applicant||Merck Europe B.V.|
|Name of medicine||Benlysta|
|Marketing-authorisation applicant||GlaxoSmithKline (Ireland) Limited|
|Name of medicine||Trulicity|
|Marketing-authorisation applicant||Eli Lilly Nederland B.V.|
Start of Community reviews - CHMP meeting of 16-19 September 2019 (PDF/96.43 KB)
First published: 20/09/2019
Scientific advice and protocol assistance adopted during the CHMP meeting 16 – 19 September 2019 (PDF/186.02 KB)Adopted
First published: 20/09/2019
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 16-19 September 2019 (PDF/172.26 KB)
First published: 25/09/2019
Last updated: 27/09/2019